Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Cogent Biosciences Announced Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosisl; Announced 89% ORR in TKI-therapy Naïve Patients; 73% ORR in All Evaluable Patients with 27-wee…

By Charles Gross
Today, 9:17 AM
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive updated clinical data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with advanced systemic m

COGT

Read More
3 minute read

Genmab Showcaseed Data From Robust Development Program Evaluating Epcoritamab in Patients Across a Broad Range of B-Cell Lymphomas at ASH 2022

By Charles Gross
Today, 9:17 AM
Genmab A/S (Nasdaq: GMAB) today announced the results from multiple clinical trials evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody, alone or in combination with other therapies for the treatment of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL

GMAB

Read More
4 minute read

Gilead’s Kites Announced Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Yescarta CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma at ASH 2022

By Charles Gross
Today, 9:17 AM
Kite, a Gilead Company (Nasdaq: GILD), today announced findings from two new analyses of the landmark ZUMA-7 trial of Yescarta® (axicabtagene ciloleucel), the largest and longest follow-up of a CAR T-cell therapy versus standard of care (SOC) in patients with relapsed or refractory large B-cell lymphoma (r/r LBCL).

GILD